Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas

Trial Profile

Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Sep 2017

At a glance

  • Drugs ENMD 2076 (Primary)
  • Indications Ovarian cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Sep 2017 According to a CASI Pharmaceuticals media release, The correlative genomics testing has been completed and a publication is expected to be submitted in 2017.
    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 18 May 2017 Status changed from recruiting to active, no longer recruiting, as reported in a CASI Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top